We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) and AstraZeneca plc (AZN - Free Report) gained fast track status in the U.S. for their experimental Alzheimer’s disease (AD) treatment, AZD3293.
AZD3293 is a BACE inhibitor that is currently in phase III studies. In addition to being in a phase II/III study (AMARANTH), patients are being enrolled in a phase III study (DAYBREAK-ALZ) that is evaluating the safety and efficacy of AZD3293 in people with mild Alzheimer's dementia.
We note that the FDA grants Fast Track status to facilitate the development and speed up the review process for candidates that are being developed for the treatment of serious conditions with an unmet medical need.
While the successful development of therapies for the treatment of Alzheimer’s disease is challenging, the market represents huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched.
According to information provided by Lilly in its press release, about 46 million people are living with dementia across the world, with the number expected to cross 74 million in 2030 and 131 million in 2050.
Lilly has another Alzheimer’s disease candidate in its pipeline – solanezumab, an anti-amyloid beta monoclonal antibody in phase III development for the treatment of preclinical and mild Alzheimer’s disease.
Lilly and AstraZeneca are both Zacks Rank #3 (Hold) stocks. Some better-ranked stocks in the health care sector include Actelion Ltd. and Zoetis Inc. (ZTS - Free Report) – while Actelion is a Zacks Rank #1 (Strong Buy) stock, Zoetis is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Eli Lilly and Company (LLY - Free Report) and AstraZeneca plc (AZN - Free Report) gained fast track status in the U.S. for their experimental Alzheimer’s disease (AD) treatment, AZD3293.
AZD3293 is a BACE inhibitor that is currently in phase III studies. In addition to being in a phase II/III study (AMARANTH), patients are being enrolled in a phase III study (DAYBREAK-ALZ) that is evaluating the safety and efficacy of AZD3293 in people with mild Alzheimer's dementia.
We note that the FDA grants Fast Track status to facilitate the development and speed up the review process for candidates that are being developed for the treatment of serious conditions with an unmet medical need.
While the successful development of therapies for the treatment of Alzheimer’s disease is challenging, the market represents huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched.
According to information provided by Lilly in its press release, about 46 million people are living with dementia across the world, with the number expected to cross 74 million in 2030 and 131 million in 2050.
Lilly has another Alzheimer’s disease candidate in its pipeline – solanezumab, an anti-amyloid beta monoclonal antibody in phase III development for the treatment of preclinical and mild Alzheimer’s disease.
LILLY ELI & CO Price
LILLY ELI & CO Price | LILLY ELI & CO Quote
Lilly and AstraZeneca’s alliance for the development and commercialization of AZD3293 goes back to 2014.
ASTRAZENECA PLC Price
ASTRAZENECA PLC Price | ASTRAZENECA PLC Quote
Lilly and AstraZeneca are both Zacks Rank #3 (Hold) stocks. Some better-ranked stocks in the health care sector include Actelion Ltd. and Zoetis Inc. (ZTS - Free Report) – while Actelion is a Zacks Rank #1 (Strong Buy) stock, Zoetis is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>